Disability Progression in Multiple Sclerosis Patients using Early First-line Treatments.

ABSTRACT:

Background

Therapeutic management of relapsing-remitting multiple sclerosis (RRMS) has evolved towards early treatment. The objective was to assess the impact of early treatment initiation on disability progression among RRMS first-line treated patients.

Methods

This study included all incident RRMS cases starting interferon or glatiramer acetate for the first time from 1996/01/01 to 2012/31/12 (N=5,279) from ten MS expert OFSEP centers (Observatoire Français de la Sclérose en Plaques). The delay from treatment start to attain an irreversible Expanded Disability Status Scale score of 3.0 were compared between "Early" group (N= 1,882; treated within 12 months following MS clinical onset) and "Later" group using propensity score weighted Kaplan-Meier methods, overall and strat

SUBMITTER: Lefort M 

PROVIDER: S-EPMC9544933 | biostudies-literature | 2022 May

REPOSITORIES: biostudies-literature